secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2026-04-08T23:59:59+00:00
Accession:  0001437749-26-011757
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell reports Q1 2026 preliminary sales up 28.4% to $10.4M; Tri-Shield up 38.5%
--------------------------------------------------------------------------------

- Total product sales $10.4M vs $8.1M in Q1 2025, a 28.4% increase.
- Domestic sales $9.7M (+35.7%); international sales $0.6M (-30.2%).
- Tri-Shield First Defense sales $7.9M (+38.5%); Dual-Force & Other $2.5M (+4.4%).
- CFO notes prior backorder situation still complicates comparisons but operational progress shown.
- Conference call scheduled for May 15, 2026 at 9:00 AM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000143774926011757/0001437749-26-011757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000143774926011757/iccc20260408_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-011757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer